Point72 Hong Kong’s Maravai LifeSciences MRVI Stock Holding History

Point72 Hong Kong’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,178	Closed	-$8.44K	–	580
2024 Q2	$8.44K	Buy	+1,178	New	+$10.2K	﹤0.01%	404
2022 Q4	–	Sell	-5,312	Closed	-$136K	–	1087
2022 Q3	$136K	Buy	5,312 +3,114	+142%	+$78.1K	﹤0.01%	1148
2022 Q2	$62K	Sell	2,198 -2,424	-52%	-$76.8K	﹤0.01%	1318
2022 Q1	$163K	Buy	+4,622	New	+$155K	0.01%	1022
2021 Q3	–	Sell	-1,072	Closed	-$45K	–	2284
2021 Q2	$45K	Buy	+1,072	New	+$41.5K	﹤0.01%	1494

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Point72 Hong Kong's MRVI Position: Q3 2024 in Review

Point72 Hong Kong sold out of Maravai LifeSciences (MRVI) in Q3 2024, closing a stake of 1,178 shares — an estimated $8.44K sold.

Point72 Hong Kong first reported a position in MRVI in Q2 2021 and held it in 5 quarters. The position peaked at $163K in Q1 2022. 217 funds tracked by Wall St. Rank hold MRVI as of Q3 2024.

Point72 Hong Kong reported no remaining Maravai LifeSciences position as of Q3 2024 after selling out during the quarter.
Point72 Hong Kong sold 1,178 Maravai LifeSciences shares in Q3 2024, an estimated $8.44K.
Point72 Hong Kong first reported a position in Maravai LifeSciences in Q2 2021 and held it in 5 quarters.
Point72 Hong Kong's Maravai LifeSciences position peaked at $163K in Q1 2022.
217 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2024.

Based on Point72 Hong Kong's 13F filing for Q3 2024, filed 14 Nov 2024.